Merck & Co. has agreed to purchase biotechnology company Afferent Pharmaceuticals, whose lead drug candidate is being evaluated as a treatment for refractory, chronic cough and idiopathic pulmonary fibrosis with cough.
from WSJ.com: US Business http://ift.tt/1WH6sv2
via IFTTT
No comments:
Post a Comment